Means and methods for detoxifying ochratoxin a

A method for detoxifying ochratoxin A (OTA) and/or altering toxicity of OTA and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, said method comprising:

• a) providing:
• (a′) one or more polypeptides capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following;
• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG;
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• (b′) one or more polynucleotides encoding and/or capable of expressing one or more polypeptides according to (a′);
• (c′) one or more nucleic acid constructs and/or expression vectors encoding and/or capable of expressing one or more polypeptides according to (a′);
• and/or
• (d′) one or more recombinant host cells, spores, transgenic plants, transgenic seeds and/or transgenic pollen grains comprising one or more of the following:
• (i′) one or more polypeptides according to (a′);
• (ii′) one or more polynucleotides according to (b′);
• and/or (iii′) one or more nucleic acid constructs and/or expression vectors according to (c′);
• preferably said one or more polypeptides are one or more recombinant and/or isolated polypeptides;
• b) applying (a) to OTA and/or to said at least one OTA derivative.

A polypeptide capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following:

• a) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2 and SEQ ID NO:
• 3;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• b) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGSPAEEGGGGKXIL
• XNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW

The polypeptide according to any one of the preceding claims, wherein said polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):

• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGSPAEEGGGGKXIL
• XNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• xvii) a polypeptide having at least 70% sequence identity (e.g. at least 70%, 74%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) to the amino acid sequence selected from the group consisting (i)-(xvi);
• xviii) a polypeptide having at least 70% identity to the amino acid sequence of (xv);
• and/or having at least 80% identity to any one of (viii)-(xiv);
• and/or having at least 90% to (vi) and/or (vii);
• xix) a variant of the polypeptide having amino acid sequence (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii) or (xiv), wherein said variant comprises a substitution, deletion, and/or insertion at one or more positions;)
• xx) a polypeptide comprising amino acid sequences:
• (i), (ii), (iii) and (iv).

The polypeptide according to any one of the preceding claims, wherein said polypeptide is one or more of the following:

• a) said polypeptide belonging to the M20 Peptidase aminoacylase 1-like protein 2-like amidohydrolase subfamily (e.g., M20 Peptidase ACY1L2 amidohydrolase subfamily, e.g., having identifier cd05672 according to the Conserved Domain Database), preferably said M20 Peptidase ACY1L2 amidohydrolase subfamily is characterized by having a metal (e.g. Zn) binding site, further preferably said metal binding site comprising an amino acid sequence motif:
• (SEQ ID NO:
• 21)
• CXHXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXE;
• and/or
• b) said polypeptide comprising:
• an amino acid C or an equivalent amino acid at a position corresponding to position 123 of SEQ ID NO:
• 1;
• an amino acid H or an equivalent amino acid at a position corresponding to position 125 of SEQ ID NO:
• 1;
• an amino acid E or an equivalent amino acid at a position corresponding to position 160 and/or 161 of SEQ ID NO:
• 1, preferably at a position corresponding to position 161 of SEQ ID NO:
• 1;
• an amino acid H or an equivalent amino acid at a position corresponding to position 185 of SEQ ID NO:
• 1;
• and an amino acid H or K, preferably H, or an equivalent amino acid at a position 383 of SEQ ID NO:
• 1;
• preferably using the numbering of SEQ ID NO:
• 1.

A recombinant host cell (e.g., an isolated recombinant host cell), spore, transgenic plant, transgenic seed or transgenic pollen grain comprising one or more of the following:

• (a′) one or more polypeptides capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following;
• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• (b′) one or more polynucleotides encoding and/or capable of expressing one or more polypeptides according to (a′);
• (c′) one or more nucleic acid constructs and/or expression vectors encoding and/or capable of expressing one or more polypeptides according to (a′).

A foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof, comprising one or more of the following:
• (a′) one or more polypeptides capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following;
• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• (b′) one or more polynucleotides encoding and/or capable of expressing one or more polypeptides according to (a′);
• (c′) one or more nucleic acid constructs and/or expression vectors encoding and/or capable of expressing one or more polypeptides according to (a′);
• and/or
• (d′) one or more recombinant host cells, spores, transgenic plants, transgenic seeds and/or transgenic pollen grains comprising one or more of the following:
• (i′) one or more polypeptides according to (a′);
• (ii′) one or more polynucleotides according to (b′);
• and/or (iii′) one or more nucleic acid constructs and/or expression vectors according to (c′);
• preferably said one or more polypeptides are one or more recombinant and/or isolated polypeptides.

A composition or kit comprising one or more of the following:

• (a′) polypeptides capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following;
• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• (b′) polynucleotides encoding and/or capable of expressing one or more polypeptides according to (a′);
• (c′) nucleic acid constructs and/or expression vectors encoding and/or capable of expressing one or more polypeptides according to (a′);
• (d′) recombinant host cells, spores, transgenic plants, transgenic seeds and/or transgenic pollen grains, foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement, prebiotic, intermediate prebiotic and/or mixture/s thereof according to any one of the preceding claims.

A foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof produced by the method according to any one of the preceding claims, wherein said foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof comprising:
• (a′) one or more polypeptides capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following;
• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• (b′) one or more polynucleotides encoding and/or capable of expressing one or more polypeptides according to (a′);
• (c′) one or more nucleic acid constructs and/or expression vectors encoding and/or capable of expressing one or more polypeptides according to (a′);
• and/or
• (d′) one or more recombinant host cells, spores, transgenic plants, transgenic seeds and/or transgenic pollen grains comprising one or more of the following:
• (i′) one or more polypeptides according to (a′);
• (ii′) one or more polynucleotides according to (b′);
• and/or (iii′) one or more nucleic acid constructs and/or expression vectors according to (c′);
• preferably said one or more polypeptides are one or more recombinant and/or isolated polypeptides.

The polypeptide (a′), wherein said polypeptide capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following:

• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• polynucleotide encoding and/or capable of expressing said polypeptides according to (a′), nucleic acid construct, expression vector encoding and/or capable of expressing one or more polypeptides according to (a′);
• recombinant host cell, spore, transgenic plant, transgenic seed, transgenic pollen grain, foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic or mixture/s thereof, composition or kit according to any one of the preceding claims;
• for use in therapy, prophylaxis and/or as a medicament (e.g., for veterinary use).

The polypeptide (a′), wherein said polypeptide capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following:

• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• polynucleotide encoding and/or capable of expressing said polypeptide according to (a′), nucleic acid construct, expression vector encoding and/or capable of expressing said polypeptide according to (a′);
• recombinant host cell, spore, transgenic plant, transgenic seed, transgenic pollen grain, foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic or mixture/s thereof, composition or kit according to any one of the preceding claims;
• for use in one or more of the following methods:
• (i) method for treatment, amelioration, prophylaxis and/or diagnostics of mycotoxicosis, preferably an OTA mycotoxicosis;
• (ii) method for monitoring development of mycotoxicosis and/or assessing the efficacy of a mycotoxicosis prophylaxis and/or therapy, preferably an OTA mycotoxicosis prophylaxis and/or therapy;
• (iii) method for detoxifying ochratoxin A (OTA) and/or altering toxicity of OTA and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C;
• (iv) method of producing one or more of the following:
• foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic;
• pharmaceutical, veterinary, diagnostic, detoxifying, monitoring and/or screening composition or kit;
• (v) method according to any one of the preceding claims;
• (vi) any combination of methods according to (i)-(v);
• (vii) method of any of (i)-(vi), wherein said method is an in vitro, ex vivo or in vivo method.

Use of one or more of the following:

• (a′) polypeptide capable of detoxifying Ochratoxin A (OTA) and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C, wherein said polypeptide is one or more of the following:
• (aa′) a polypeptide having at least 64% (e.g., at least 69% or at least 80% or at least 85% or at least 95%, preferably at least 69%) sequence identity to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4;
• preferably said polypeptide having an amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1-3;
• further preferably said polypeptide having SEQ ID NO:
• 1;
• (aaa′) a polypeptide comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i)
• (SEQ ID NO:
• 5)
• GHACGHNLIA;
• ii)
• (SEQ ID NO:
• 6)
• IGSPAEEGGGGK;
• iii)
• (SEQ ID NO:
• 7)
• MAHP;
• iv)
• (SEQ ID NO:
• 23)
• VNHT;
• v)
• (SEQ ID NO:
• 9)
• KVAKGLA;
• vi)
• (SEQ ID NO:
• 10)
• IGSPAEEGGGGKVIL;
• vii)
• (SEQ ID NO:
• 11)
• AHAGAAPWLG;
• viii)
• (SEQ ID NO:
• 12)
• PELGFHEVKA;
• ix)
• (SEQ ID NO:
• 13)
• TNPTSLPTAFVAT;
• x)
• (SEQ ID NO:
• 14)
• GGRTFGFNAEYDAL;
• xi)
• (SEQ ID NO:
• 15)
• GHACGHNLIAIVAVASA;
• xii)
• (SEQ ID NO:
• 16)
• IPGTIKVIGSPAEEGGGGKVILLNEG;
• xiii)
• (SEQ ID NO:
• 17)
• DACVMAHPEGG;
• xiv)
• (SEQ ID NO:
• 18)
• AHAGAAPWLGVNALDAAVQGY;
• xv)
• (SEQ ID NO:
• 19)
• GHACGHNLIAXXAVAXAXGXKAAXXXXXIXGTXKXIGS
• PAEEGGGGKXILXNEGXYDXXDACXMAHPXGG,
• wherein X is any amino acid;
• xvi)
• (i), (ii), (iii) and (iv);
• and/or
• xvii)
• (SEQ ID NO:
• 8)
• AHAGAAPW;
• (b′) polynucleotide encoding and/or capable of expressing said polypeptide according to (a′) or nucleic acid construct or expression vector encoding and/or capable of expressing said polypeptide according to (a′),
• (d′) recombinant host cell, spore, transgenic plant, transgenic seed, transgenic pollen grain, foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic or mixture/s thereof, composition or kit according to any one of the preceding claims;
• for/in one or more of the following:
• (i) treatment, amelioration, prophylaxis and/or diagnostics of mycotoxicosis, preferably OTA mycotoxicosis;
• (ii) monitoring development of mycotoxicosis and/or assessing the efficacy of a mycotoxicosis prophylaxis and/or therapy, preferably OTA mycotoxicosis prophylaxis and/or therapy;
• (iii) detoxifying ochratoxin A (OTA) and/or altering toxicity of OTA and/or at least one OTA derivative, wherein said OTA derivative is preferably selected from the group consisting of Ochratoxin B and Ochratoxin C;
• (iv) producing one or more of the following:
• foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic;
• pharmaceutical, veterinary, diagnostic, detoxifying, monitoring and/or screening composition or kit;
• (v) in method according to any one of the preceding claims;
• (vi) any combination of according to (i)-(v);
• (vii) use of any of (i)-(vi), wherein said use is an in vitro, ex vivo or in vivo use.